
Full text loading...
Category: Clinical Microbiology
Shiga Toxin/Verocytotoxin-Producing Escherichia coli Infections: Practical Clinical Perspectives, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555818791/9781555818784_Chap15-1.gif /docserver/preview/fulltext/10.1128/9781555818791/9781555818784_Chap15-2.gifAbstract:
Shiga toxin (Stx)-producing Escherichia coli (STEC) cause illness with a spectrum of severity ranging from mild (even asymptomatic) carriage to life-threatening disease ( 1 – 3 ). STEC infections are relatively uncommon; in the United States, extrapolation of data from FoodNet ( 4 ) to a nationwide population that exceeds 300,000,000 indicates there are fewer than 4,000 diagnosed cases of E. coli O157:H7 infection per annum. E. coli O157:H7 remains the near-exclusive cause of hemolytic-uremic syndrome (HUS) throughout most of the world, and the single serotype on which most data have been generated. Therefore, we emphasize this particular pathogen in this article. The European Food Safety Authority and the European Centre for Disease Prevention and Control report similar epidemiology: 4,000 confirmed infections caused by Stx-producing E. coli strains (mostly belonging to the O157 serogroup) in 27 European Union member states. The number of reported infections attributed to E. coli strains that produce Shiga toxins has increased since 2008 ( 5 ).
Full text loading...
Acuity pyramid a
Summary of antibiotic experience in multiple case control studies of children and adults a
Severity of HUS in series identified in PubMed published between 2009 and 2013, using search terms hemolytic-uremic syndrome AND children, on September 4, 2013 a
Selected nonnephrologic, nonhematologic complications of HUS